Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma
Credit: Sarah Cannon (WASHINGTON, October 4, 2018) -- For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease...





